1. International Agency for Research on Cancer. GLOBOCAN 2008. 2008. cited by 2010 Sep. Lyon: IARC;Available from:
http://globocan.iarc.fr.
2. Jung YS, Na KY, Kim KS, Ahn SH, Lee SJ, Park HK, et al. Nation-wide Korean breast cancer data from 2008 using the breast cancer registration program. J Breast Cancer. 2011. 14:229–236.
3. Son BH, Kwak BS, Kim JK, Kim HJ, Hong SJ, Lee JS, et al. Changing patterns in the clinical characteristics of Korean patients with breast cancer during the last 15 years. Arch Surg. 2006. 141:155–160.
4. Chang MC. Estimating relative risk of breast cancer in Korean women using computer program. J Korean Breast Cancer Soc. 2004. 7:294–298.
5. Euhus DM. Understanding mathematical models for breast cancer risk assessment and counseling. Breast J. 2001. 7:224–232.
6. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 1998. 90:1371–1388.
7. Dunn BK, Ford LG. From adjuvant therapy to breast cancer prevention: BCPT and STAR. Breast J. 2001. 7:144–157.
8. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989. 81:1879–1886.
9. Evans DG, Howell A. Breast cancer risk-assessment models. Breast Cancer Res. 2007. 9:213.
10. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991. 265:1985–1990.
11. Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev. 2003. 4:157–173.
12. Mitchell G, Antoniou AC, Warren R, Peock S, Brown J, Davies R, et al. Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res. 2006. 66:1866–1872.
13. Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet. 2003. 40:807–814.
14. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006. 15:1159–1169.
15. Kato I, Beinart C, Bleich A, Su S, Kim M, Toniolo PG. A nested case-control study of mammographic patterns, breast volume, and breast cancer (New York City, NY, United States). Cancer Causes Control. 1995. 6:431–438.
16. Saftlas AF, Hoover RN, Brinton LA, Szklo M, Olson DR, Salane M, et al. Mammographic densities and risk of breast cancer. Cancer. 1991. 67:2833–2838.
17. Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst. 1995. 87:1622–1629.
18. Torres-Mejía G, De Stavola B, Allen DS, Pérez-Gavilán JJ, Ferreira JM, Fentiman IS, et al. Mammographic features and subsequent risk of breast cancer: a comparison of qualitative and quantitative evaluations in the Guernsey prospective studies. Cancer Epidemiol Biomarkers Prev. 2005. 14:1052–1059.
19. Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res. 2011. 13:223.
20. Wee CW, Kang M, Seo KY, Choe YH, Min YK, Lee DY, et al. Impact of oral levonorgestrel for 1 year on mammographic density in menopausal hormone therapy. J Korean Soc Menopause. 2011. 17:27–33.
21. Ryu KY, Chung DH, Chung CY, Cho SH, Cho SH, Hwang YY, et al. Effect of hormone replacement therapy on mammographic density change in postmenopausal women. J Korean Soc Menopause. 1998. 4:93–99.
22. Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C, et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst. 2006. 98:1215–1226.